Asebio Investor Day, meeting point for specialized biotechnology investment
Asebio has brought together 60 investors interested in Spanish biotech projects from 9 countries. More than five-hundred opportunities for companies participating in partnering meetings
As part of European Biotech Week, the Spanish Bioindustry Association (Asebio) is hosting its second annual Asebio Investor Day.
This investment forum, which has put innovative Spanish biotechnology projects in touch with foreign and local investors, has hosted 280 participants, 60 investors from 9 countries and over 500 closed partnering meetings.
Asebio Investor Day featured various panel discussions on current topics in funding early stage biotechnology projects and how, in recent years, new vehicles and types of investment have come on the scene, like venture capital funds, corporate investors, crowdfunding, impact investing and public initiatives.
The participating start-ups represent a broad cross-section of the industry, with applications in innovative areas like advanced therapies, oncology, neurodegenerative diseases, cardiology, and a long etcetera.
All-time record investment in biotechnology
Since 2008, venture capital funds that invest in biotechnology have raised nearly €600 million.
In Spain, 2018 saw the consolidation of positive results of specialized investment, with both more and larger private capital increases, totaling nearly €95 million.
Foreign investment continues to grow
Establishing a local ecosystem of specialized venture capital companies has been key in boosting the industry with the funding needed to start up new companies, grow and get results. Their role has been fundamental, not only for the funds invested and the expertise they contribute, but also in attracting private investment from international players.
So much so that rounds with international funding made up €40 million of the €64 million in private investment in 2016, €70 of the €94 million in 2017 and €74 of the €95 million in 2018.
The sector is showing growing maturity and, in recent years, has attracted investment from top benchmark countries like France, Belgium, United States and Japan.
Asebio highlighted, “We firmly believe in the role of specialized investors, both venture capital and corporate investors, in providing funding, smart money, to boost the development of our biotechnology ecosystem”, said Ion Arocena, CEO of Asebio.
“We also believe that venture capital investment is crossing borders more and more, and the ties between local and foreign investors is key for attracting investment to our industry”, concluded Arocena.
Asebio Investor Day is organized jointly with the Alternative Equity Market-BME; the Platform of Biotechnological Markets-Ministry of Science, Innovation and Universities; and the Institute of Foreign Trade-ICEX.